GlassScriptPhysician profile
Joseph Albert Labio Abijay
NPI 1225032899
$16,983.95
in general payments reported to CMS, 2019-2025
50 companies · $2,327 in 2025
The $2,327 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,343 · 2020: $1,981 · 2021: $3,339 · 2022: $2,721 · 2023: $2,381 · 2024: $2,891 · 2025: $2,327.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,450 · Consulting Fee: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,449.78 |
| Consulting Fee | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,068.37 | 2019-2025 | Ubrelvy, Qulipta, Duopa |
| Pfizer INC. | $1,199.43 | 2021-2025 | |
| Biogen, INC. | $1,170.44 | 2019-2025 | Vumerity, Tysabri, Spinraza |
| Teva Pharmaceuticals USA, INC. | $983.63 | 2019-2025 | Austedo Xr, Austedo Xr |
| Amgen INC. | $916.66 | 2019-2025 | Uplizna, Aimovig |
| Lilly USA, LLC | $828.54 | 2020-2025 | Emgality, Reyvow, Amyvid |
| Supernus Pharmaceuticals, INC. | $665.75 | 2019-2025 | Qelbree |
| Novartis Pharmaceuticals Corporation | $659.04 | 2019-2024 | |
| Neurocrine Biosciences, INC. | $646.13 | 2019-2025 | Ingrezza, Ongentys |
| Abbott Laboratories | $473.16 | 2022-2025 | Infinity |
| Genentech USA, INC. | $449.07 | 2019-2025 | Ocrevus, Ocrevus Zunovo |
| Biohaven Pharmaceutical Holding Company LTD. | $396.09 | 2022 | |
| Sk Life Science, INC. | $387.42 | 2020-2024 | |
| Biohaven Pharmaceuticals, INC. | $384.65 | 2020-2021 | |
| Amneal Pharmaceuticals LLC | $381.08 | 2021-2025 | Rytary, Crexont |
Show all 50 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $346.40 | 2019-2021 | |
| Ucb, INC. | $344.70 | 2019-2024 | Nayzilam, Briviact |
| Kyowa Kirin, INC. | $338.12 | 2019-2024 | Nourianz |
| Celgene Corporation | $317.85 | 2021-2025 | Zeposia |
| Upsher-Smith Laboratories LLC | $298.00 | 2019-2021 | |
| Allergan, INC. | $242.62 | 2020 | |
| Acadia Pharmaceuticals INC | $241.58 | 2020-2025 | Nuplazid |
| Lundbeck LLC | $228.56 | 2020-2025 | Vyepti, Rexulti |
| Mdd US Operations, LLC | $213.30 | 2019-2025 | Gocovri, Gocovri |
| Genzyme Corporation | $188.61 | 2019-2022 | |
| Acorda Therapeutics, INC | $184.60 | 2019-2023 | Inbrija |
| Emd Serono, INC. | $161.71 | 2019-2021 | |
| Grifols USA, LLC | $129.77 | 2021-2025 | Gamunex-C |
| Neurelis, INC. | $128.59 | 2020-2024 | Valtoco |
| Argenx US, INC. | $119.41 | 2022-2025 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $107.64 | 2023-2025 | Rexulti, Nuedexta |
| E.R. Squibb & Sons, L.L.C. | $105.09 | 2020-2021 | |
| Horizon Therapeutics Plc | $90.63 | 2021-2023 | Uplizna |
| Zyla Life Sciences, INC. | $84.65 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $63.51 | 2024-2025 | Ponvory |
| Eisai INC. | $57.92 | 2024-2025 | |
| Medtronic, INC. | $44.08 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.87 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $37.67 | 2019 | |
| Axsome Therapeutics, INC. | $29.88 | 2025 | Symbravo |
| Octapharma USA, INC. | $28.76 | 2022 | |
| Janssen Biotech, INC. | $26.67 | 2025 | |
| Ani Pharmaceuticals, INC. | $26.44 | 2024 | Purified Cortrophin Gel |
| Jazz Pharmaceuticals INC. | $23.85 | 2025 | |
| Csl Behring | $23.03 | 2019 | |
| Vertical Pharmaceuticals, LLC | $22.88 | 2019 | |
| Arbor Pharmaceuticals, INC. | $22.71 | 2021 | |
| Ge Healthcare | $22.04 | 2025 | |
| Mallinckrodt Enterprises LLC | $21.24 | 2019 | |
| Harmony Biosciences LLC | $13.11 | 2023 | Wakix |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joseph Abijay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.